CymaBay Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of CymaBay Therapeutics generated cash of -$72,531,000, which is more than the previous year. Cash used in financing activities reached the amount of $345,772,000 last year. Net change in cash is therefore $186,244,000.
Cash Flow
| 2014 | -21.11M | -16.93M | 25.23M |
|---|---|---|---|
| 2015 | -23.32M | -11.08M | 30.52M |
| 2016 | -23.35M | 27.12M | -986K |
| 2017 | -19.63M | -67.52M | 99.71M |
| 2018 | -54.93M | -54.11M | 134.98M |
| 2019 | -97.91M | -34.34M | 108.13M |
| 2020 | -44.72M | 47.95M | 92K |
| 2021 | -69.43M | 48.58M | 118.45M |
| 2022 | -84.08M | -45.98M | 24.55M |
| 2023 | -72.53M | -86.56M | 345.77M |
0I5P.L Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 20.29M | 125.80M | 28.19M | 24.86M | 48.99M | 23.05M | 10.49M | 7.70M | 11.58M | 24.40M |
Operating activities | ||||||||||
Net income | -105.37M | -106.00M | -89.99M | -50.98M | -102.80M | -72.54M | -27.55M | -26.67M | -15.52M | -31.91M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 681K | 710K | 688K | 632K | 800K | 105K | 35K | 29K | 22K | 18K |
Stock-based compensation expense | 0 | 9.51M | 9.99M | 7.32M | 6.10M | 7.01M | 4.92M | 2.47M | 2.48M | 1.29M |
| Deferred income tax benefit | 0 | 9.51M | 9.99M | 7.32M | 6.10M | 7.01M | 4.92M | 2.47M | 2.48M | 1.29M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 5M | -5M | 0 | 0 | -101K |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 2.73M | -1.44M | 2.30M | -2.27M | 530K | 0 | 0 | 0 | 0 | 0 |
Cash generated by operating activities | -72.53M | -84.08M | -69.43M | -44.72M | -97.91M | -54.93M | -19.63M | -23.35M | -23.32M | -21.11M |
Investing activities | ||||||||||
Purchases Of Investments | -305.67M | -174.97M | -78.08M | -176.3M | -290.89M | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -445K | -148K | -87K | -21K | -315K | -529K | -27K | -42K | 0 | -103K |
Acquisitions Net | 0 | 45.83M | -48.67M | -47.97M | 34.03M | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -86.56M | -45.98M | 48.58M | 47.95M | -34.34M | -54.11M | -67.52M | 27.12M | -11.08M | -16.93M |
Financing activities | ||||||||||
Common Stock Issued | 345.77M | 0 | 70.71M | 92K | 108.13M | 0 | 0 | 0 | 0 | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | -47.73M | 0 | 0 | -6.52M | 0 | -986K | 0 | -244K |
Cash used in financing activities | 345.77M | 24.55M | 118.45M | 92K | 108.13M | 134.98M | 99.71M | -986K | 30.52M | 25.23M |
Net Change In Cash | 186.24M | -105.51M | 97.61M | 3.32M | -24.12M | 25.94M | 12.55M | 2.78M | -3.88M | -12.81M |
Cash at end of period | 206.53M | 20.29M | 125.80M | 28.19M | 24.86M | 48.99M | 23.05M | 10.49M | 7.70M | 11.58M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |